Johnson & Johnson's subcutaneous regimen for NSCLC shows strong safety profile at WCLC 2026
Executive summary: Johnson & Johnson presented data at WCLC 2026 showing that Rybrevant Faspro plus Lazcluze exhibits low rates of rash, blood clots, and administration-related reactions when used with prophylactic strategies. Improved safety profiles and subcutaneous delivery options increase patient adherence and ease the burden of treatment for non-small cell lung cancer patients.
Who is involved: Johnson & Johnson
Likely next: Potential regulatory review or expanded label indications based on these safety outcomes.
At the WCLC 2026 conference, new data for Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) combined with Lazcluze (lazertinib) revealed low rates of treatment-related adverse events. The subcutaneous administration and prophylactic strategies resulted in fewer than 1% of patients discontinuing the treatment due to side effects at the one-year mark. This reinforces the clinical utility of the combination in managing non-small cell lung cancer.
What's next — scenarios
Base: Continued clinical adoption (65%)
Wider usage of the combination in frontline NSCLC due to manageable safety profile.
- Long-term follow-up data confirming durability
- Regulatory approval for subcutaneous formulation
Upside: Market dominance in EGFR-mutated NSCLC (25%)
Shift in standard of care away from traditional intravenous regimens.
- Superiority trials against current standard-of-care
- Health technology assessment (HTA) favorable reimbursement
Downside: Emergence of unforeseen long-term toxicity (10%)
Regulatory restrictions or increased warnings for the combination.
- Long-term safety data showing delayed adverse events
What to watch
- Follow-up data from ongoing WCLC 2026 presentations
- FDA/EMA regulatory decisions on subcutaneous Rybrevant Faspro
Timeline
- — RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026 (PR Newswire)
- — Ivonescimab Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC: Positive Overall Survival Results from HARMONi-2 Presented at WCLC 2026 (PR Newswire)
- — AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline (PR Newswire)
- — Nuvation Bio to Present New Subgroup Analyses of Pivotal Data for IBTROZI® (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses (PR Newswire)
Analysis — what this means
Likely next events
- WCLC 2026 conference updates
- Future FDA advisory committee meetings on NSCLC biologics
Sectors affected
- Oncology biotechnology
- Pharmaceutical manufacturing
- Specialty drug distribution
Historical parallels
- MARIPOSA clinical program
Key entities
Sources
- RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026 — PR Newswire
- Ivonescimab Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC: Positive Overall Survival Results from HARMONi-2 Presented at WCLC 2026 — PR Newswire
- AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline — PR Newswire
- Nuvation Bio to Present New Subgroup Analyses of Pivotal Data for IBTROZI® (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses — PR Newswire
Related cases
- Akeso's Ivonescimab achieves positive overall survival results against Pembrolizumab in first-line NSCLC treatment
- PTK7 emerges as stable ADC target in EGFR wild-type NSCLC, boosting Whitehawk's HWK-007 prospects
- Akeso's Ivonescimab demonstrates superior overall survival compared to Pembrolizumab in PD-L1-positive NSCLC
- SystImmune’s Phase 1 data for Iza-bren show promising activity in EGFR‑mutated lung cancer, backing a 2.5 mg/kg dose for Phase 3